Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity
2022/09/27 by Franziska Sotzny, Igor Salerno Filgueiras, Claudia Kedor +24 · 1 voice · 113 citations
Medicine · #Antibody #Asymptomatic #Autoantibody #Chronic fatigue syndrome #Disease #Encephalomyelitis #Fibromyalgia and Chronic Fatigue Syndrome Research #Heart Rate Variability and Autonomic Control #Immunology #Internal medicine #Long-Term Effects of COVID-19 #Medicine #Multiple sclerosis #Pathogenesis #Receptor
paper · doi:10.3389/fimmu.2022.981532
published in Frontiers in Immunology 13, 981532 (Frontiers Media)
openalex publication_date 2022/09/27 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/06
Abstract
Most patients with Post COVID Syndrome (PCS) present with a plethora of symptoms without clear evidence of organ dysfunction. A subset of them fulfills diagnostic criteria of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Symptom severity of ME/CFS correlates with natural regulatory autoantibody (AAB) levels targeting several G-protein coupled receptors (GPCR). In this exploratory study, we analyzed serum AAB levels against vaso- and immunoregulatory receptors, mostly GPCRs, in 80 PCS patients following mild-to-moderate COVID-19, with 40 of them fulfilling diagnostic criteria of ME/CFS. Healthy seronegative (n=38) and asymptomatic post COVID-19 controls (n=40) were also included in the study as control groups. We found lower levels for various AABs in PCS compared to at least one control group, accompanied by alterations in the correlations among AABs. Classification using random forest indicated AABs targeting ADRB2, STAB1, and ADRA2A as the strongest classifiers (AABs stratifying patients according to disease outcomes) of post COVID-19 outcomes. Several AABs correlated with symptom severity in PCS groups. Remarkably, severity of fatigue and vasomotor symptoms were associated with ADRB2 AAB levels in PCS/ME/CFS patients. Our study identified dysregulation of AAB against various receptors involved in the autonomous nervous system (ANS), vaso-, and immunoregulation and their correlation with symptom severity, pointing to their role in the pathogenesis of PCS.
Citations
Cited by
- An In-Depth Exploration of the Autoantibody Immune Profile in ME/CFS Using Novel Antigen Profiling Techniques
- Neuroimmune pathophysiology of long COVID
- Immunoadsorption Versus Sham Treatment for Post-COVID Syndrome: A Randomised Sham-Controlled Crossover Trial
- Autoantibodies in long COVID in a black/mixed population compared with recovered and pre-pandemic controls
- Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT)
- Novel biomarkers of mitochondrial dysfunction in Long COVID patients
- Immunoglobulin G complexes from post-infectious ME/CFS, including post-COVID ME/CFS disrupt cellular energetics and alter inflammatory marker secretion
- Breaking the silence: Recognizing post-vaccination syndrome
- Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID
- A causal link between autoantibodies and neurological symptoms in long COVID
- Association of circulating biomarkers with illness severity measures differentiates myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 condition: a prospective pilot cohort study
- Therapeutic Approaches to Dysautonomia in Childhood, with a Special Focus on Long COVID. [europepmc]
- Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment. [europepmc]
- Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets. [europepmc]
- ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. [europepmc]
- Molecular mimicry and autoimmunity in the time of COVID-19. [europepmc]
- Fighting Post-COVID and ME/CFS - development of curative therapies. [europepmc]
- Association analysis between symptomology and herpesvirus IgG antibody concentrations in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and multiple sclerosis. [europepmc]
- [S1 guidelines for the management of postviral conditions using the example of post-COVID-19]. [europepmc]
- Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: a systems biology approach. [europepmc]
- Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort. [europepmc]
- Epstein-Barr virus-acquired immunodeficiency in myalgic encephalomyelitis-Is it present in long COVID? [europepmc]
- Autonomic dysregulation in long-term patients suffering from Post-COVID-19 Syndrome assessed by heart rate variability. [europepmc]
- Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated ß2-Adrenergic Receptor Autoantibodies-An Interim Report. [europepmc]
- Pediatric and adult patients with ME/CFS following COVID-19: A structured approach to diagnosis using the Munich Berlin Symptom Questionnaire (MBSQ). [europepmc]
- Exploring the joint potential of inflammation, immunity, and receptor-based biomarkers for evaluating ME/CFS progression. [europepmc]
- IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS). [europepmc]
- Randomized controlled double-blind trial of methylprednisolone versus placebo in patients with post-COVID-19 syndrome and cognitive deficits: study protocol of the post-corona-virus immune treatment (PoCoVIT) trial. [europepmc]
- Association of circulating biomarkers with illness severity measures differentiates myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 condition: a prospective pilot cohort study. [europepmc]
- Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches. [europepmc]
- Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone. [europepmc]
- Autoantibodies in COVID-19 survivors with post-COVID symptoms: a systematic review. [europepmc]
- Novel biomarkers of mitochondrial dysfunction in Long COVID patients. [europepmc]
- Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study. [europepmc]
- Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health. [europepmc]
- Neuroimmune pathophysiology of long COVID. [europepmc]
Discussions
Related